Description
3ml of bacteriostatic water included
Overview:
AOD 9604 is a synthetic peptide fragment derived from the C-terminal region
(amino acids 176–191) of human growth hormone (hGH). It was developed to
isolate potential fat-metabolism effects of growth hormone while minimizing
effects on growth and insulin-like growth factor-1 (IGF-1).
Proposed Mechanism (Preclinical Research)
Research suggests AOD 9604 may:
- Stimulate lipolysis (breakdown of stored fat)
- Inhibit lipogenesis (formation of new fat)
- Act on adipose tissue without significantly affecting blood glucose levels
- Avoid strong stimulation of IGF-1 pathways associated with full-length growth hormone
Unlike growth hormone itself, AOD 9604 is designed to target metabolic
pathways more selectively.
Research Areas
AOD 9604 has been investigated in:
- Obesity research
- Fat metabolism studies
- Weight management models
- Cartilage repair research (exploratory studies)
Clinical trials have been conducted in obesity, but large-scale regulatory
approvals for prescription use have not been broadly established in major
markets.
Evidence & Regulatory Status
- Studied in human clinical trials for obesity
- Not widely approved as a prescription medication
- Often sold as “research use only” in non-pharmaceutical formulations
- Long-term safety data remain limited outside formal clinical development programs
FOR RESEARCH USE ONLY
